US2003050250A1PendingUtilityA1

Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agents

43
Priority: Mar 4, 1999Filed: Dec 10, 2001Published: Mar 13, 2003
Est. expiryMar 4, 2019(expired)· nominal 20-yr term from priority
Inventors:Jay CunninghamGary B. GordonGeorge A. NickolsWilliam Frederick Westlin, IiiThomas E. RogersPeter G. Ruminski
A61P 43/00A61P 9/00A61P 35/04A61P 7/00A61P 3/14A61P 29/00A61P 35/00A61P 19/08A61K 31/704C07D 239/14A61K 31/675A61P 19/02A61K 31/505A61K 33/243
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to compounds of the formula and pharmaceutically acceptable salts and isomers thereof administered in combination with chemotherapeutic agents.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of administering a compound of the formula  
       
         
           
           
               
               
           
         
         wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent.  
       
     
     
         2 . A method according to  claim 1  wherein the chemotherapeutic agent is selected from the group consisting of cisplatin; cyclophosphamide; 5-fluorouracil, doxorubicin and taxol.  
     
     
         3 . A method according to  claim 1  wherein the compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
     
     
         4 . A method according to  claim 3  wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.  
     
     
         5 . A method of treating or preventing a neoplasia disease comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:  
       
         
           
           
               
               
           
         
         wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent.  
       
     
     
         6 . A method according to  claim 5  wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.  
     
     
         7 . A method according to  claim 5  wherein the compound is selected from the group consisting of  
       
         
           
           
               
               
           
         
       
     
     
         8 . A method according to  claim 7  wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.  
     
     
         9 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to  claim 1 , a chemotherapeutic agent and a pharmaceutically acceptable carrier.  
     
     
         10 . A method according to  claim 5  wherein the neoplasia disease is tumor metastasis.  
     
     
         11 . A method according to  claim 5  wherein the neoplasia disease treated is solid tumor growth.  
     
     
         12 . A method according to  claim 5  wherein the condition treated is angiogenesis.  
     
     
         13 . A method according to  claim 5  wherein the neoplasia disease is humoral hypercalcemia of malignancy.

Join the waitlist — get patent alerts

Track US2003050250A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.